The AMPA receptor as a therapeutic target in epilepsy: Preclinical and clinical evidence

Journal of Receptor, Ligand and Channel Research

Volumn 7, Issue , 2014, Pages 39-50

  Hanada, Takahisa ^a,b  

^a EISAI CO LTD   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Anticonvulsant; Antiepileptic; Drug discovery research; Epileptogenesis; Glutamate; Perampanel; Seizure; Synaptic plasticity

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; DOMOIC ACID; FANAPANEL; PERAMPANEL; TALAMPANEL;

ABSENCE; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; HUMAN; MEMBRANE PERMEABILITY; NERVE CELL PLASTICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; TRANSGENIC ANIMAL;

EID: 84908076508     PISSN: None     EISSN: 1178699X     Source Type: Journal    
DOI: 10.2147/JRLCR.S51475     Document Type: Review

References (141)

1. Abu Saleh T, Stephen L. Lennox gastaut syndrome, review of the literature and a case report. Head Face Med. 2008;4:9.
2. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883-890.
3. Shorvon SD, Goodridge DM. Longitudinal cohort studies of the prognosis of epilepsy: contribution of the National General Practice Study of Epilepsy and other studies. Brain. 2013;136(Pt 11):3497-3510.
4. French JA, White HS, Klitgaard H, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia. 2013;54 Suppl 4:3-12.
5. Galanopoulou AS, Kokaia M, Loeb JA, et al. Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia. 2013;54 Suppl 4:13-23.
6. Wilcox KS, Dixon-Salazar T, Sills GJ, et al. Issues related to development of new antiseizure treatments. Epilepsia. 2013;54 Suppl 4:24-34.
7. Lason W, Chlebicka M, Rejdak K. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep. 2013;65(4):787-801.
8. McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol. 2001;63:815-846.
9. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience. 1985;14(2):375-403.
10. Cendes F, Andermann F, Carpenter S, Zatorre RJ, Cashman NR. Temporal lobe epilepsy caused by domoic acid intoxication: evidence for glutamate receptor-mediated excitotoxicity in humans. Ann Neurol. 1995;37(1):123-126.
11. Turski L, Jacobsen P, Honoré T, Stephens DN. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J Pharmacol Exp Ther. 1992;260(2):742-747.
12. Turski W, Turski L, Czuczwar SJ, Kleinrok Z. (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid: wet dog shakes, catalepsy and body temperature changes in rats. Pharmacol Biochem Behav. 1981;15(4):545-549.
13. Smith M, Wilcox KS, White HS. Discovery of antiepileptic drugs. Neurotherapeutics. 2007;4(1):12-17.
14. Löscher W, Schmidt D. Epilepsy: Perampanel-new promise for refractory epilepsy? Nat Rev Neurol. 2012;8(12):661-662.
15. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861-9866.
16. Featherstone DE. Intercellular glutamate signaling in the nervous system and beyond. ACS Chem Neurosci. 2010;1(1):4-12.
17. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000;130(Suppl 4S):1007S-1015S.
18. Seeburg PH. The TINS/TiPS lecture. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci. 1993;16(9): 359-365.
19. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11(2):56-63.
20. Mansour M, Nagarajan N, Nehring RB, Clements JD, Rosenmund C. Heteromeric AMPA receptors assemble with a preferred subunit stoichiometry and spatial arrangement. Neuron. 2001;32(5):841-853.
21. Hollmann M, Hartley M, Heinemann S. Ca2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science. 1991;252(5007):851-853.
22. Geiger JR, Melcher T, Koh DS, et al. Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron. 1995;15(1):193-204.
23. He Y, Janssen WG, Vissavajjhala P, Morrison JH. Synaptic distribution of GluR2 in hippocampal GABAergic interneurons and pyramidal cells: a double-label immunogold analysis. Exp Neurol. 1998;150(1):1-13.
24. de Lanerolle NC, Eid T, von Campe G, Kovacs I, Spencer DD, Brines M. Glutamate receptor subunits GluR1 and GluR2/3 distribution shows reorganization in the human epileptogenic hippocampus. Eur J Neurosci. 1998;10(5):1687-1703.
25. Kessels HW, Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron. 2009;61(3):340-350.
26. Kobylecki C, Crossman AR, Ravenscroft P. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia. Exp Neurol. 2013;247:476-484.
27. Liu SJ, Zukin RS. Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 2007;30(3):126-134.
28. Liu Y, Formisano L, Savtchouk I, et al. A single fear-inducing stimulus induces a transcription-dependent switch in synaptic AMPAR phenotype. Nat Neurosci. 2010;13(2):223-231.
29. Jakowec MW, Jackson-Lewis V, Chen X, Langston JW, Przedborski S. The postnatal development of AMPA receptor subunits in the basal ganglia of the rat. Dev Neurosci. 1998;20(1):19-33.
30. Monyer H, Seeburg PH, Wisden W. Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron. 1991;6(5):799-810.
31. Acosta G, Freidman DP, Grant KA, Hemby SE. Alternative splicing of AMPA subunits in prefrontal cortical fields of cynomolgus monkeys following chronic ethanol self-administration. Front Psychiatry. 2012;2:72.
32. Eastwood SL, Burnet PW, Harrison PJ. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Brain Res Mol Brain Res. 1997;44(1):92-98.
33. Gitaí DL, Martinelli HN, Valente V, et al. Increased expression of GluR2-flip in the hippocampus of the Wistar audiogenic rat strain after acute and kindled seizures. Hippocampus. 2010;20(1):125-133.
34. Guan Y, Guo W, Zou SP, Dubner R, Ren K. Inflammation-induced upregulation of AMPA receptor subunit expression in brain stem pain modulatory circuitry. Pain. 2003;104(1-2):401-413.
35. Kamphuis W, Monyer H, De Rijk TC, Lopes da Silva FH. Hippocampal kindling increases the expression of glutamate receptor-A flip and -B flip mRNA in dentate granule cells. Neurosci Lett. 1992;148(1-2):51-54.
36. Seifert G, Hüttmann K, Schramm J, Steinhäuser C. Enhanced relative expression of glutamate receptor 1 flip AMPA receptor subunits in hippocampal astrocytes of epilepsy patients with Ammon's horn sclerosis. J Neurosci. 2004;24(8):1996-2003.
37. Partin KM, Patneau DK, Mayer ML. Cyclothiazide differentially modulates desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants. Mol Pharmacol. 1994;46(1):129-138.
38. Quirk JC, Nisenbaum ES. Multiple molecular determinants for allosteric modulation of alternatively spliced AMPA receptors. J Neurosci. 2003;23(34):10953-10962.
39. Sumioka A. Auxiliary subunits provide new insights into regulation of AMPA receptor trafficking. J Biochem. 2013;153(4):331-337.
40. Straub C, Tomita S. The regulation of glutamate receptor trafficking and function by TARPs and other transmembrane auxiliary subunits. Curr Opin Neurobiol. 2012;22(3):488-495.
41. Menuz K, Stroud RM, Nicoll RA, Hays FA. TARP auxiliary subunits switch AMPA receptor antagonists into partial agonists. Science. 2007;318(5851):815-817.
42. Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. Neuron. 2013;80(3):704-717.
43. Plant K, Pelkey KA, Bortolotto ZA, et al. Transient incorporation of native GluR2-lacking AMPA receptors during hippocampal long-term potentiation. Nat Neurosci. 2006;9(5):602-604.
44. Chen SR, Zhou HY, Byun HS, Pan HL. Nerve injury increases GluA2-lacking AMPA receptor prevalence in spinal cords: functional significance and signaling mechanisms. J Pharmacol Exp Ther. 2013;347(3): 765-772.
45. Hanley JG. Subunit-specific trafficking mechanisms regulating the synaptic expression of Ca(2+)-permeable AMPA receptors. Semin Cell Dev Biol. 2014;27:14-22.
46. Rajasekaran K, Joshi S, Kozhemyakin M, et al. Receptor trafficking hypothesis revisited: plasticity of AMPA receptors during established status epilepticus. Epilepsia. 2013;54 Suppl 6:14-16.
47. Silverdale MA, Kobylecki C, Hallett PJ, et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse. 2010;64(2): 177-180.
48. Whitehead G, Jo J, Hogg EL, et al. Acute stress causes rapid synaptic insertion of Ca2+-permeable AMPA receptors to facilitate long-term potentiation in the hippocampus. Brain. 2013;136(Pt 12):3753-3765.
49. Costa LG, Giordano G, Faustman EM. Domoic acid as a developmental neurotoxin. Neurotoxicology. 2010;31(5):409-423.
50. Larm JA, Beart PM, Cheung NS. Neurotoxin domoic acid produces cytotoxicity via kainate- and AMPA-sensitive receptors in cultured cortical neurones. Neurochem Int. 1997;31(5):677-682.
51. Teitelbaum JS, Zatorre RJ, Carpenter S, et al. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med. 1990;322(25):1781-1787.
52. Lothman EW, Collins RC, Ferrendelli JA. Kainic acid-induced limbic seizures: electrophysiologic studies. Neurology. 1981;31(7):806-812.
53. Zhang J, Wang Y, Chi Z, et al. The AAA+ ATPase thorase regulates AMPA receptor-dependent synaptic plasticity and behavior. Cell. 2011;145(2):284-299.
54. Graebenitz S, Kedo O, Speckmann EJ, et al. Interictal-like network activity and receptor expression in the epileptic human lateral amygdala. Brain. 2011;134(Pt 10):2929-2947.
55. Hosford DA, Crain BJ, Cao Z, et al. Increased AMPA-sensitive quisqualate receptor binding and reduced NMDA receptor binding in epileptic human hippocampus. J Neurosci. 1991;11(2):428-434.
56. Ying Z, Babb TL, Comair YG, Bushey M, Touhalisky K. Increased densities of AMPA GluR1 subunit proteins and presynaptic mossy fiber sprouting in the fascia dentata of human hippocampal epilepsy. Brain Res. 1998;798(1-2):239-246.
57. Coombs ID, Soto D, Zonouzi M, et al. Cornichons modify channel properties of recombinant and glial AMPA receptors. J Neurosci. 2012;32(29):9796-9804.
58. Swanson GT, Kamboj SK, Cull-Candy SG. Single-channel properties of recombinant AMPA receptors depend on RNA editing, splice variation, and subunit composition. J Neurosci. 1997;17(1):58-69.
59. Grossman SD, Wolfe BB, Yasuda RP, Wrathall JR. Alterations in AMPA receptor subunit expression after experimental spinal cord contusion injury. J Neurosci. 1999;19(14):5711-5720.
60. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46(3):409-427.
61. Gower AJ, Noyer M, Verloes R, Gobert J, Wülfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol. 1992;222(2-3):193-203.
62. White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia. 2003;44 Suppl 7:2-8.
63. Durmuller N, Craggs M, Meldrum BS. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 1994;17(2): 167-174.
64. Namba T, Morimoto K, Sato K, Yamada N, Kuroda S. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 1994;638(1-2): 36-44.
65. Barton ME, Peters SC, Shannon HE. Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res. 2003;56(1):17-26.
66. Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47(3):217-227.
67. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7): 1331-1340.
68. Milstein AD, Nicoll RA. Regulation of AMPA receptor gating and pharmacology by TARP auxiliary subunits. Trends Pharmacol Sci. 2008;29(7):333-339.
69. Barad Z, Shevtsova O, Arbuthnott GW, Leitch B. Selective loss of AMPA receptors at corticothalamic synapses in the epileptic stargazer mouse. Neuroscience. 2012;217:19-31.
70. Menuz K, Nicoll RA. Loss of inhibitory neuron AMPA receptors contributes to ataxia and epilepsy in stargazer mice. J Neurosci. 2008;28(42):10599-10603.
71. Beyer B, Deleuze C, Letts VA, et al. Absence seizures in C3H/HeJ and knockout mice caused by mutation of the AMPA receptor subunit Gria4. Hum Mol Genet. 2008;17(12):1738-1749.
72. Russo E, Citraro R, De Fazio S, et al. Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy. Epilepsy Behav. 2008;13(2):295-299.
73. Jakus R, Graf M, Ando RD, et al. Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res. 2004;1008(2):236-244.
74. Micheletti G, Vergnes M, Marescaux C, et al. Antiepileptic drug evaluation in a new animal model: spontaneous petit mal epilepsy in the rat. Arzneimittelforschung. 1985;35(2):483-485.
75. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.
76. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251-256.
77. Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. Predictors of outcome in refractory status epilepticus. JAMA Neurol. 2013;70(1):72-77.
78. Sutter R, Marsch S, Fuhr P, Rüegg S. Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study. Epilepsia. 2013;54(3):502-511.
79. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(Pt 8):2314-2328.
80. Patneau DK, Vyklicky L Jr, Mayer ML. Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate. J Neurosci. 1993;13(8):3496-3509.
81. Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SJ, Kleinrok Z, Turski L. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav Brain Res. 1983;9(3):315-335.
82. Walton NY, Treiman DM. Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Exp Neurol. 1988;101(2):267-275.
83. Goodkin HP, Joshi S, Mtchedlishvili Z, Brar J, Kapur J. Subunit-specific trafficking of GABA(A) receptors during status epilepticus. J Neurosci. 2008;28(10):2527-2538.
84. Rajasekaran K, Todorovic M, Kapur J. Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus. Ann Neurol. 2012;72(1):91-102.
85. Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52446. Epilepsia. 2010;51(1): 108-117.
86. Langer M, Brandt C, Zellinger C, Löscher W. Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology. 2011;61(5-6):1033-1047.
87. Pitkänen A, Mathiesen C, Ronn LC, Møller A, Nissinen J. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res. 2007;74(1):45-54.
88. Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF. The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther. 2011;336(2):303-312.
89. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 2007;75(2-3):192-196.
90. Pitkänen A, Nehlig A, Brooks-Kayal AR, et al. Issues related to development of antiepileptogenic therapies. Epilepsia. 2013;54 Suppl 4:35-43.
91. Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epileptic Disord. 2012;14(2):105-113.
92. Sun H, Kosaras B, Klein PM, Jensen FE. Mammalian target of rapamycin complex 1 activation negatively regulates polo-like kinase 2-mediated homeostatic compensation following neonatal seizures. Proc Natl Acad Sci U S A. 2013;110(13):5199-5204.
93. Li SY, Xu DS, Jia HT. AGS-induced expression of Narp is concomitant with expression of AMPA receptor subunits GluR1 and GluR2 in hippocampus but not inferior colliculus of P77PMC rats. Neurobiol Dis. 2003;14(3):328-335.
94. Sommer C, Roth SU, Kiessling M. Kainate-induced epilepsy alters protein expression of AMPA receptor subunits GluR1, GluR2 and AMPA receptor binding protein in the rat hippocampus. Acta Neuropathol. 2001;101(5):460-468.
95. Prince HC, Tzingounis AV, Levey AI, Conn PJ. Functional downregulation of GluR2 in piriform cortex of kindled animals. Synapse. 2000;38(4):489-498.
96. Sanchez RM, Koh S, Rio C, et al. Decreased glutamate receptor 2 expression and enhanced epileptogenesis in immature rat hippocampus after perinatal hypoxia-induced seizures. J Neurosci. 2001;21(20): 8154-8163.
97. Talos DM, Sun H, Zhou X, et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One. 2012;7(5):e35885.
98. van der Kooij MA, Ohl F, Arndt SS, Kavelaars A, van Bel F, Heijnen CJ. Mild neonatal hypoxia-ischemia induces long-term motor- and cognitive impairments in mice. Brain Behav Immun. 2010;24(5):850-856.
99. Talos DM, Follett PL, Folkerth RD, et al. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex. J Comp Neurol. 2006;497(1):61-77.
100. Talos DM, Fishman RE, Park H, et al. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex. J Comp Neurol. 2006;497(1):42-60.
101. Rakhade SN, Fitzgerald EF, Klein PM, et al. Glutamate receptor 1 phosphorylation at serine 831 and 845 modulates seizure susceptibility and hippocampal hyperexcitability after early life seizures. J Neurosci. 2012;32(49):17800-17812.
102. Aujla PK, Fetell MR, Jensen FE. Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Epilepsia. 2009;50(4):694-701.
103. Jensen FE, Blume H, Alvarado S, Firkusny I, Geary C. NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. Epilepsia. 1995;36(10):966-972.
104. Lippman-Bell JJ, Rakhade SN, Klein PM, et al. AMPA receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures. Epilepsia. 2013;54(11):1922-1932.
105. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33(2):67-75.
106. Guo D, Zeng L, Brody DL, Wong M. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PLoS One. 2013;8(5):e64078.
107. Russo E, Citraro R, Donato G, et al. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology. 2013;69:25-36.
108. Ryther RC, Wong M. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy. Curr Neurol Neurosci Rep. 2012;12(4):410-418.
109. Grant KA, Colombo G, Grant J, Rogawski MA. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology. 1996;35(12):1709-1719.
110. Muller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry. 1995;28(4):113-124.
111. Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm Gen Sect. 1993;92(1):57-65.
112. Löscher W, Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J Pharmacol Exp Ther. 1991;256(2):432-440.
113. Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993;15(3):179-184.
114. Walters MR, Kaste M, Lees KR, et al. The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc Dis. 2005;20(5):304-309.
115. Hibi S, Ueno K, Nagato S, et al. Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med Chem. 2012;55(23):10584-10600.
116. Tarnawa I, Farkas S, Berzsenyi P, Pataki A, Andrási F. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur J Pharmacol. 1989;167(2):193-199.
117. Tarnawa I, Farkas S, Berzsenyi P, Pátfalusi M, Andrási F. Reflex inhibitory action of a non-NMDA type excitatory amino acid antagonist, GYKI 52466. Acta Physiol Hung. 1990;75 Suppl:277-278.
118. Weiser T. AMPA receptor antagonists for the treatment of stroke. Curr Drug Targets CNS Neurol Disord. 2005;4(2):153-159.
119. Faught E. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs. 2014;23(1): 107-113.
120. Gomez-Mancilla B, Brand R, Jürgens TP, et al. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia. 2014;34(2):103-113.
121. Chappell AS, Sander JW, Brodie MJ, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology. 2002;58(11):1680-1682.
122. Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amytroph Lateral Scler. 2010;11(3):266-271.
123. Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol. 2009;27(25): 4155-4161.
124. Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003;44(1):46-53.
125. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009; 61(2):197-216.
126. European Medicines Agency. Fycompa [summary of product characteristics]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf. Accessed February 28, 2014.
127. Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia. 2009;50 Suppl 11:98.
128. Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov. 2014;9(4): 449-458.
129. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589-596.
130. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1): 117-125.
131. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408-1415.
132. Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54(8):1490-1497.
133. Kerling F, Kasper BS. Efficacy of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl. 2013;(s197):25-29.
134. Serratosa JM, Villanueva V, Kerling F, Kasper BS. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand. 2013;127 Suppl 197:30-35.
135. Steinhoff BJ, Laurenza A, Yang H, Satlin A. Safety profile of perampanel as an adjunctive treatment for partial-onset seizures. J Symptoms Signs. 2014;3(2):64-70.
136. Steinhoff BJ. Efficacy of perampanel: a review of pooled data. Epilepsia. 2014;55 Suppl 1:9-12.
137. US Food and Drug Administration. Fycompa [prescribing information]. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.pdf. Accessed February 28, 2014.
138. Bagal SK, Brown AD, Cox PJ, et al. Ion channels as therapeutic targets: a drug discovery perspective. J Med Chem. 2013;56(3):593-624.
139. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28(2):75-82.
140. Vink S, Alewood PF. Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain. Br J Pharmacol. 2012;167(5):970-989.
141. Parsons CG, Gilling K. Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker. Methods Mol Biol. 2007;403:15-36.